Key result
18F-FDG PET/CT altered therapy planning in 80 of 345 scans (16.4% for staging and 29.9% for restaging) in patients with soft-tissue sarcomas.
Why the study?
The exact role and added value of 18F-FDG PET/CT over computed tomography and magnetic resonance imaging in therapy planning for soft-tissue sarcomas is not well established.
Does 18F-FDG PET/CT influence therapy planning in patients with soft-tissue sarcomas?
Observational (n=282)
No
Does 18F-FDG PET/CT influence therapy planning in patients with soft-tissue sarcomas?
18F-FDG PET/CT significantly influences the clinical management and therapy planning of patients with soft-tissue sarcomas, particularly during restaging.
Answers are grounded in this paper and cite their sources.
May inform selective management in soft-tissue sarcomas; leaves open need for prospective outcome data before routine adoption.
Background: Soft-tissue sarcomas (STS) represent a wide heterogeneous class of rare tumors. The exact role 18F-fluorodeoxyglucose positron emission/computed tomography (18F-FDG PET/CT) in the evaluation of STS is not well established. The aim of the present study was to evaluate how the use of 18F-FDG PET/CT in STS could influence patient therapy planning, looking for a possible added value over computed tomography and magnetic resonance imaging—the most used modalities in the study of STS. Differences in SUVmax according to histologic subtype and tumor grade were also considered. Methods: a total of 345 consecutive 18F-FDG PET/CT scans performed for initial staging (n = 171) or for suspected disease relapse (n = 174) in 282 patients with STS extracted from the local Information System database were retrospectively reviewed. Results: 18F-FDG PET/CT altered therapy planning in 80 cases (16.4% for staging and 29.9% in restaging), both for disease upstaging (58.8%) and downstaging (41.2%) Conclusions: 18F-FDG PET/CT could significantly influence management of patients with STS, particularly for restaging.
No takes yet. Share an insight, caveat, or question.
Annovazzi et al. (2020) conducted an observational in Soft-tissue sarcomas (n=282). 18F-FDG PET/CT was evaluated on Alteration of therapy planning. 18F-FDG PET/CT altered therapy planning in 80 of 345 scans (16.4% for staging and 29.9% for restaging) in patients with soft-tissue sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: